The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...

As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...

GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

South Africa is a good example of a country that would benefit from the discovery of a cure. South Africa’s been providing ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.19 which represents a slight increase of $0.43 or 0.48% from the prior close of $89.76. The stock opened at $89 ...